{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:26:44Z","timestamp":1784795204941,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Labour Sciences Research Grant","award":["23EA1036"],"award-info":[{"award-number":["23EA1036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15711-1","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:47:35Z","timestamp":1770958055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing chemotherapy regimens and dosing for older patients with metastatic pancreatic cancer: insights from the Tokushukai real-world data project"],"prefix":"10.1186","volume":"26","author":[{"given":"Sakue","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rai","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Uryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahisa","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Shiragami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"15711_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"15711_CR2","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Go\u00e9r\u00e9 D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56-68.","journal-title":"Ann Oncol"},{"key":"15711_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"15711_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"15711_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardi\u00e8re C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"issue":"11","key":"15711_CR6","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/healthcare10112146","volume":"10","author":"R Shimoyama","year":"2022","unstructured":"Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, et al. Real-world outcomes of systemic therapy in Japanese patients with cancer (Tokushukai REAl-world data project: TREAD): study protocol for a nationwide cohort study. Healthcare. 2022;10(11):2146. https:\/\/doi.org\/10.3390\/healthcare10112146.","journal-title":"Healthcare"},{"key":"15711_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3892\/mco.2023.2694","volume":"19","author":"R Shimoyama","year":"2023","unstructured":"Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, et al. Real\u2011world treatment outcomes among patients with metastatic pancreatic cancer in Japan: the Tokushukai real\u2011world data project. Mol Clin Oncol. 2023;19:98.","journal-title":"Mol Clin Oncol"},{"key":"15711_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/ije\/dyx232","volume":"47","author":"VL Gordon-Dseagu","year":"2018","unstructured":"Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427\u201339.","journal-title":"Int J Epidemiol"},{"key":"15711_CR9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/jjco\/hyy148","volume":"48","author":"A Okuyama","year":"2018","unstructured":"Okuyama A, Saika K. Pancreas cancer incidence rates in the world from the Cancer Incidence in Five Continents XI. Jpn J Clin Oncol. 2018;48:1028\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"15711_CR10","unstructured":"Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. Cancer incidence (1975\u20132020): Pancreas; age distribution. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html. Accessed 15\u00a0July\u00a02025."},{"key":"15711_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/ggi.13118","volume":"17","author":"Y Ouchi","year":"2017","unstructured":"Ouchi Y, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17:1045\u20137.","journal-title":"Geriatr Gerontol Int"},{"key":"15711_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M, Kitano M, Ito Y, Mizuno N, et al. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: A synopsis. Int J Clin Oncol. 2023;28:493\u2013511.","journal-title":"Int J Clin Oncol"},{"key":"15711_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/cas.12501","volume":"105","author":"T Okusaka","year":"2014","unstructured":"Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, et al. Phase II study of folfirinox for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321\u20136.","journal-title":"Cancer Sci"},{"key":"15711_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pan.2016.12.009","volume":"17","author":"C Baldini","year":"2017","unstructured":"Baldini C, Escande A, Bouch\u00e9 O, El Hajbi F, Volet J, Bourgeois V, et al. Safety and efficacy of folfirinox in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Pancreatology. 2017;17:146\u20139.","journal-title":"Pancreatology"},{"key":"15711_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002.","journal-title":"Ann Oncol"},{"issue":"4","key":"15711_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439\u201357.","journal-title":"J Natl Compr Canc Netw."},{"key":"15711_CR17","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38:3217\u201330.","journal-title":"J Clin Oncol"},{"issue":"Supple 2","key":"15711_CR18","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","volume":"34","author":"A Ohba","year":"2023","unstructured":"Ohba A, Ozaka M, Ogawa G, Okusaka T, Kobayashi S, Yamashita T, et al. Nab-paclitaxel plus gemcitabine versus modified folfirinox or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II\/III trial. ESMO Congress 2023;1616O. Ann Oncol. 2023;34(Supple 2):S894.","journal-title":"Ann Oncol."},{"key":"15711_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","volume":"7","author":"PS Hall","year":"2021","unstructured":"Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: The GO2 Phase 3 randomized clinical trial. JAMA Oncol. 2021;7:869\u201377.","journal-title":"JAMA Oncol"},{"key":"15711_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S2468-1253(19)30041-X","volume":"4","author":"SB Winther","year":"2019","unstructured":"Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen L\u00d8, et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2019;4:376\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"15711_CR21","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1093\/oncolo\/oyac157","volume":"27","author":"S Kobayashi","year":"2022","unstructured":"Kobayashi S, Suzuki M, Ueno M, Maruki Y, Okano N, Todaka A, et al. Comparing the Efficacy and Safety of gemcitabine plus Nab-Paclitaxel versus gemcitabine Alone in Older Adults with unresectable Pancreatic Cancer. Oncologist. 2022;27:e774\u201382.","journal-title":"Oncologist"},{"key":"15711_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2020.11.003","volume":"143","author":"GW Prager","year":"2021","unstructured":"Prager GW, Oehler L, Gerger A, Mlineritsch B, Andel J, Petzer A, et al. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: analysis of a multicentre, prospective, non-interventional study. Eur J Cancer. 2021;143:101\u201312.","journal-title":"Eur J Cancer"},{"key":"15711_CR23","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26:e1609-18-e1618.","journal-title":"Oncologist"},{"key":"15711_CR24","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1097\/MPA.0000000000001942","volume":"51","author":"K Iede","year":"2022","unstructured":"Iede K, Yamada T, Koh M, Ueda M, Tsuda Y, Nakashima S, et al. Optimal relative dose intensity in the first 4 weeks during nab-paclitaxel plus gemcitabine for older patients with advanced pancreatic cancer in Japan. Pancreas. 2022;51:e4-6.","journal-title":"Pancreas"},{"key":"15711_CR25","unstructured":"National Cancer Center. Japan. National Cancer Registry (Ministry of Health, Labour and Welfare) tabulated by Cancer Information Service. https:\/\/ganjoho.jp\/med_pro\/cancer_control\/can_reg\/index.html. Accessed 8 May 2024."},{"key":"15711_CR26","unstructured":"National Cancer Institute.\u00a0Common Terminology Criteria for Adverse Events (CTCAE) v5.0.\u202f2017. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 15\u00a0Jul\u00a02025."},{"key":"15711_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377\u201399.","journal-title":"Stat Med"},{"key":"15711_CR28","unstructured":"Rubin Db. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons Inc.. - references - scientific research publishing; 1987. https:\/\/www.scirp.org\/%28S%28lz5mqp453edsnp55rrgjct55%29%29\/reference\/ReferencesPapers.aspx?ReferenceID=1374692. Accessed 10 Oct 2023."},{"key":"15711_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12935-020-01558-4","volume":"20","author":"H Zhang","year":"2020","unstructured":"Zhang H, Ren D, Jin X, Wu H. The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. Cancer Cell Int. 2020;20:462.","journal-title":"Cancer Cell Int"},{"key":"15711_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12885-020-07110-x","volume":"20","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Feeney K, Lee MA, Mu\u00f1oz A, Graci\u00e1n AC, Lonardi S, et al. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer. 2020;20:633.","journal-title":"BMC Cancer"},{"key":"15711_CR31","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.21873\/anticanres.12927","volume":"38","author":"JP Grabowski","year":"2018","unstructured":"Grabowski JP, Richter R, Rittmeister H, Chekerov R, Woopen H, Sehouli J. Impact of body mass index (BMI) on chemotherapy-associated toxicity in ovarian cancer patients. A pooled analysis of the North-Eastern German society of gynecological oncology (NOGGO) databank on 1,213 patients. Anticancer Res. 2018;38:5853\u20138.","journal-title":"Anticancer Res"},{"key":"15711_CR32","first-page":"100344","volume":"3","author":"H Tu","year":"2022","unstructured":"Tu H, McQuade JL, Davies MA, Huang M, Xie K, Ye Y, et al. Body mass index and survival after cancer diagnosis: a pan-cancer cohort study of 114 430 patients with cancer. Innovation (Camb). 2022;3:100344.","journal-title":"Innovation (Camb)"},{"key":"15711_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12282-020-01194-w","volume":"28","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang S, Yee D, Basu S, Beckwith H, Potter D, et al. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. Breast Cancer (Tokyo). 2021;28:618\u201329.","journal-title":"Breast Cancer (Tokyo)"},{"key":"15711_CR34","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1200\/JCO.2013.51.7532","volume":"31","author":"C Yuan","year":"2013","unstructured":"Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013;31:4229\u201334.","journal-title":"J Clin Oncol"},{"key":"15711_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12885-023-10989-x","volume":"23","author":"Y Murakawa","year":"2023","unstructured":"Murakawa Y, Ootsuka K, Kusaka J, Miura K. Correlation between overall survival and quality of life in colon cancer patients with chemotherapy. BMC Cancer. 2023;23:492.","journal-title":"BMC Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15711-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:56:17Z","timestamp":1774281377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15711-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15711"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15711-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by the Ethics Committee of the Tokushukai Group in April 2020 (approval number: TGE01427-024) and conducted according to the principles outlined in the Declaration of Helsinki. The patients provided consent using the opt-out method.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}